“Eli Lilly and Novo Nordisk are cutting prices for popular weight-loss drugs in deals struck with the Trump administration, which is expanding coverage of the drugs in the Medicare and Medicaid health-insurance programs.
The companies will sell their GLP-1-containing drugs, including Novo Nordisk's Ozempic and Wegovy, and Eli Lilly's Mounjaro and Zepbound, to the Medicare and Medicaid programs for $245 a month, to treat both diabetes and obesity, according to senior administration officials.
Medicare patients will pay a copay of $50 a month starting as early as April 2026.
Outside of the government programs, Lilly and Novo Nordisk will sell injected GLP-1-containing drugs directly to consumers at an average price of $350 a month, with commitments to bring that down to about $250 over the next two years.
In exchange, Lilly will get a reprieve from potential new tariffs, and won't be subject to any new drug-pricing programs initiated by the Trump administration. The Food and Drug Administration is granting special new vouchers to Lilly and Novo Nordisk that are intended to speed up the agency's review of their proposed new weight-loss pills.” [1]
1. U.S. News: Obesity Drug Prices Cut In Deal. Loftus, Peter. Wall Street Journal, Eastern edition; New York, N.Y.. 07 Nov 2025: A3.
Komentarų nėra:
Rašyti komentarą